Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Sign Up
PubMed This is a summary of 20 peer-reviewed journal articles Updated
Ophthalmology · Gyrate Atrophy of the Choroid and Retina

Treatment and Metabolic Management

At a Glance

Gyrate atrophy is managed by lowering toxic ornithine levels with an individualized, supervised arginine-restricted diet and, for some genetic variants, a vitamin B6 trial. Eye complications such as edema, new blood vessels, and cataracts need specialist treatment.

Treating Gyrate Atrophy is a long-term commitment that focuses on managing the body’s chemistry to protect the eyes. Because high levels of ornithine are toxic to the retina, the primary goal is to lower these levels as early and as consistently as possible. Management requires a coordinated effort between a metabolic specialist, a dietitian, and an ophthalmologist [1][2].

CRITICAL SAFETY WARNING: Never change your protein intake, restrict your diet, or start high-dose vitamin supplements without direct supervision from your metabolic team. Unsupervised restriction can lead to malnutrition, loss of muscle, or impaired growth.

The Arginine-Restricted Diet

The cornerstone of treatment is a highly specialized diet that restricts arginine, an amino acid found in protein-rich foods like meat, dairy, nuts, and beans [3]. By limiting arginine, the body produces less ornithine, which can slow the progression of retinal damage.

  • Timing is Key: Evidence from patient cohorts suggests that starting a protein-restricted diet before the age of 10 is associated with significantly better visual field outcomes later in life [4][5].
  • Individualized Targets: There is no “one-size-fits-all” diet. Doctors typically prescribe a specific target—for example, between 0.6 to 0.8 grams of protein per kilogram of body weight per day in certain studies—but this must be highly individualized based on age, growth, and nutritional status [3][6].
  • Monitoring: Success is measured through frequent blood tests to track plasma ornithine levels. In some cases, maintaining levels below 500 µmol/L has been linked to stabilized vision, though individual results vary and this is not a universally guaranteed target [7][3].
  • Potential Risks: Because the diet is so restrictive, it must be supervised to prevent malnutrition. Some patients may experience reduced muscle (fat-free) mass or developmental delays if the diet is not properly balanced [1][2].

The Vitamin B6 (Pyridoxine) Trial

About 30% of investigated genetic variants of Gyrate Atrophy are “responsive” to Vitamin B6 (pyridoxine) [8]. For these individuals, high doses of B6 can help the remaining OAT enzyme work more effectively, lowering ornithine levels without requiring an extremely strict diet.

  • The Test Protocol: Doctors usually perform a supervised trial, which in some studies used doses between 200 and 500 mg per day for two to three weeks [3][9]. WARNING: High-dose vitamin B6 can cause severe and potentially permanent peripheral sensory neuropathy (numbness and tingling). Do not attempt this over the counter.
  • Measuring Response: A positive response is typically defined by a significant drop in plasma ornithine levels (sometimes 30% or more) during the trial [10][3].
  • Genetic Influence: Certain mutations, such as the V332M variant, are more likely to respond, while others are known to be non-responsive [11][12].

Managing Eye Complications

While the diet manages the underlying cause, specific treatments are often needed for complications that arise within the eye. These must be individualized by your retina specialist.

  • Cystoid Macular Edema (CME) and Foveoschisis: For fluid buildup (CME) or splitting (foveoschisis) in the central retina, doctors may use carbonic anhydrase inhibitor eye drops (like brinzolamide) or systemic medications [13][14]. In some cases, injections of anti-VEGF medications (like bevacizumab) are used, though results for CME in Gyrate Atrophy can be mixed and are often off-label [15][16]. Foveoschisis and CME are separate issues and may require different approaches.
  • Macular Neovascularization (MNV): If abnormal blood vessels begin to leak (a serious “red flag”), intravitreal anti-VEGF injections are the standard of care to dry the retina and preserve central vision [17][18].
  • Cataracts: Early-onset cataracts are common and are managed through standard cataract surgery, which can significantly improve visual clarity [1][5].

Future Research

Scientists are currently exploring gene therapy (specifically using an AAV8 vector) to deliver a healthy OAT gene directly to cells. While this has shown promise in animal studies by reducing ornithine and improving retinal function, it is currently in early-stage preclinical research and is not yet available for clinical use in humans [19][20]. Monitoring clinical trial registries can provide updates on when human trials may begin.

Common questions in this guide

How does diet help treat gyrate atrophy?
An individualized arginine- and protein-restricted diet can reduce the amount of ornithine the body produces. It must be designed and monitored by a metabolic specialist and dietitian because overly strict restriction can cause malnutrition, muscle loss, or impaired growth.
Does starting a low-protein diet early improve gyrate atrophy outcomes?
Studies of patients with gyrate atrophy suggest that starting protein restriction before age 10 is associated with better visual-field outcomes later in life. The right protein and arginine targets vary with age, growth, and nutritional status, so they must be prescribed and adjusted by the care team.
Can vitamin B6 lower ornithine in gyrate atrophy?
A supervised vitamin B6 trial may lower ornithine in people whose genetic variant responds to pyridoxine; about 30% of investigated variants have been reported as responsive. High doses can cause severe and potentially permanent nerve damage, so vitamin B6 should never be started or adjusted without medical supervision.
How are cystoid macular edema and foveoschisis treated in gyrate atrophy?
Treatment depends on which retinal problem is present and may include carbonic anhydrase inhibitor eye drops, systemic medicines, or anti-VEGF injections. Cystoid macular edema and foveoschisis are different conditions, and an ophthalmologist or retina specialist must individualize the approach.
What happens if macular neovascularization develops?
Macular neovascularization involves abnormal blood vessels that can leak and threaten central vision. Intravitreal anti-VEGF injections are the standard treatment used to reduce leakage and help preserve vision.
Is gene therapy available for gyrate atrophy?
AAV8 gene therapy is being studied in animal models and has shown early promise for lowering ornithine and improving retinal function. It remains preclinical research and is not currently available as a routine treatment for people.

Get notified when new evidence is published on Gyrate atrophy of choroid and retina.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (20)
  1. 1

    Clinical, biochemical and molecular analysis in a cohort of individuals with gyrate atrophy.

    Palmer E, Stepien KM, Campbell C, et al.

    Orphanet journal of rare diseases 2023; (18(1)):265 doi:10.1186/s13023-023-02840-0.

    PMID: 37667371
  2. 2

    Gyrate atrophy of the choroid and retina: a tertiary center experience.

    Aktaşoğlu EÖ, Özdemir HB, Özmen MC, et al.

    Orphanet journal of rare diseases 2026; (21(1)).

    PMID: 41699715
  3. 3

    Metabolic follow-up of a Croatian patient with gyrate atrophy and a new mutation in the OAT gene: a case report.

    Zekušić M, Škaričić A, Fumić K, et al.

    Biochemia medica 2018; (28(3)):030801 doi:10.11613/BM.2018.030801.

    PMID: 30429681
  4. 4

    Novel Insights Into Gyrate Atrophy of the Choroid and Retina (GACR): A Cohort Study.

    Balfoort BM, Van den Broeck F, Boon CJF, et al.

    Journal of inherited metabolic disease 2025; (48(1)):e12842 doi:10.1002/jimd.12842.

    PMID: 39761806
  5. 5

    A cohort study of 19 patients with gyrate atrophy of the choroid and retina (GACR).

    Balfoort BM, Van Den Broeck F, Brands MM, et al.

    Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie 2024; (262(11)):3589-3596 doi:10.1007/s00417-024-06540-8.

    PMID: 38847892
  6. 6

    Reversal of cystoid macular edema in gyrate atrophy patients.

    Heller D, Weiner C, Nasie I, et al.

    Ophthalmic genetics 2017; (38(6)):549-554 doi:10.1080/13816810.2017.1301966.

    PMID: 28388263
  7. 7

    A possible ocular biomarker for response to hyperornithinemia in gyrate atrophy: the effect of pyridoxine, lysine, and arginine-restricted diet in a patient with advanced disease.

    da Palma MM, Ku C, Igelman AD, et al.

    Ophthalmic genetics 2023; (44(2)):191-197 doi:10.1080/13816810.2022.2098986.

    PMID: 35856163
  8. 8

    A review of treatment modalities in gyrate atrophy of the choroid and retina (GACR).

    Balfoort BM, Buijs MJN, Ten Asbroek ALMA, et al.

    Molecular genetics and metabolism 2021; (134(1-2)):96-116 doi:10.1016/j.ymgme.2021.07.010.

    PMID: 34340878
  9. 9

    Partial regression of foveoschisis following vitamin B6 supplementary therapy for gyrate atrophy in a Chinese girl.

    Guan W, Wang G, Hu F, Peng X

    BMC ophthalmology 2021; (21(1)):93 doi:10.1186/s12886-021-01862-1.

    PMID: 33602140
  10. 10

    Multimodal characterization of a novel mutation causing vitamin B6-responsive gyrate atrophy.

    Cui X, Jauregui R, Park KS, Tsang SH

    Ophthalmic genetics 2018; (39(4)):512-516 doi:10.1080/13816810.2018.1474370.

    PMID: 29757052
  11. 11

    Molecular and cellular basis of ornithine δ-aminotransferase deficiency caused by the V332M mutation associated with gyrate atrophy of the choroid and retina.

    Montioli R, Desbats MA, Grottelli S, et al.

    Biochimica et biophysica acta. Molecular basis of disease 2018; (1864(11)):3629-3638 doi:10.1016/j.bbadis.2018.08.032.

    PMID: 30251682
  12. 12

    Extending diagnostic practices in gyrate atrophy: Enzymatic characterization and the development of an in vitro pyridoxine responsiveness assay.

    Balfoort BM, Pampalone G, Ruiter JPN, et al.

    Molecular genetics and metabolism 2024; (143(1-2)):108542 doi:10.1016/j.ymgme.2024.108542.

    PMID: 39053126
  13. 13

    Regression of macular edema with topical brinzolamide and nepafenac alone and identification of a novel gyrate atrophy mutation.

    Çavdarlı C, Şahlı E, Çavdarlı B, Alp MN

    Arquivos brasileiros de oftalmologia 2020; (83(2)):149-152 doi:10.5935/0004-2749.20200028.

    PMID: 32159596
  14. 14

    Carbonic Anhydrase Inhibitor with Topical NSAID Therapy to Manage Cystoid Macular Edema in a Case of Gyrate Atrophy.

    Piozzi E, Alessi S, Santambrogio S, et al.

    European journal of ophthalmology 2017; (27(6)):e179-e183 doi:10.5301/ejo.5001010.

    PMID: 28708224
  15. 15

    Treatment of Intraretinal Cystic Spaces Associated With Gyrate Atrophy of the Choroid and Retina With Intravitreal Bevacizumab.

    Elnahry AG, Aboulfotouh MR, Nassar GA

    Journal of pediatric ophthalmology and strabismus 2020; (57(6)):400-406 doi:10.3928/01913913-20200813-01.

    PMID: 33211898
  16. 16

    Regression of treatment-resistant gyrate atrophy-associated intraretinal cystic spaces using long-term diet restriction: A case report.

    Elhusseiny AM, Haseeb A, Elnahry AG

    European journal of ophthalmology 2023; (33(3)):NP1-NP4 doi:10.1177/11206721221085868.

    PMID: 35243906
  17. 17

    Macular neovascularization in patients with Gyrate atrophy.

    Bierbrier J, Ahmed Y, Ventresca M, et al.

    Ophthalmic genetics 2026; 1-7 doi:10.1080/13816810.2026.2671407.

    PMID: 42220020
  18. 18

    Bilateral choroidal neovascularization associated with gyrate atrophy managed with intravitreal bevacizumab.

    Inanc M, Tekin K, Teke MY

    International ophthalmology 2018; (38(3)):1351-1355 doi:10.1007/s10792-017-0579-2.

    PMID: 28560651
  19. 19

    Liver-directed gene therapy for ornithine aminotransferase deficiency.

    Boffa I, Polishchuk E, De Stefano L, et al.

    EMBO molecular medicine 2023; (15(4)):e17033 doi:10.15252/emmm.202217033.

    PMID: 36647689
  20. 20

    Combined intraocular and intravenous gene delivery for therapy of gyrate atrophy of the choroid and retina.

    Dell'Aquila F, Di Cunto R, Marrocco E, et al.

    Molecular therapy : the journal of the American Society of Gene Therapy 2025; (33(7)):2997-3005 doi:10.1016/j.ymthe.2024.10.019.

    PMID: 39489914

This page is for informational purposes only and does not constitute medical advice. Protein restriction, vitamin B6 trials, and eye treatments for gyrate atrophy must be planned and monitored by your metabolic team and ophthalmologist.

Guide contents Gyrate atrophy of choroid and retina
Research & Literature
04 Diagnostic Testing and Lab Reports 06 Long-Term Monitoring and Living with Gyrate Atrophy